Skip to main content
Contact Us
Subscribe
E-Edition
74°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
135.42
-5.45 (-3.87%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
54
55
Next >
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand
February 22, 2024
Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Move Over Magnificent 7, Say Hello to the GRANOLAS
February 22, 2024
Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods.
Via
InvestorPlace
2 No-Brainer Biotech Stocks to Buy Right Now
February 21, 2024
These stocks are used to beating the market.
Via
The Motley Fool
Weight-Loss Drugs Vs. Conagra Foods: Company Optimistic Amid Shifting Consumer Demands Influenced By Hunger Suppressing
February 21, 2024
Conagra Brands' optimistic outlook at a Conference addressing concerns about weight-loss drugs impacting U.S. food companies. Executive backs positivity with Numerator data, citing an 8% rise in...
Via
Benzinga
7 Analysts Assess Novo Nordisk: What You Need To Know
February 20, 2024
Via
Benzinga
Novo Nordisk Unusual Options Activity For February 14
February 14, 2024
Via
Benzinga
NYSE:NVO is not too expensive for the growth it is showing.
February 14, 2024
Investors seeking growth at a reasonable cost should explore NYSE:NVO.
Via
Chartmill
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
February 13, 2024
Via
Benzinga
3 Top Sectors Investment Dollars Are Pouring Into Now: February 2024
February 20, 2024
Predicting top sectors isn't easy; we usually identify them only in hindsight, but these three stock market segments are rapidly rising.
Via
InvestorPlace
3 Cheap Dividend Stocks to Snatch Up Now
February 20, 2024
Cheap dividend stocks offer rebound upside paired with an income source that is difficult to beat for most investors.
Via
InvestorPlace
Ozempic Effect: Food Industry Feels The Heat As Weight-Loss Drugs Get Popular, Investors Call For Menu Makeovers
February 20, 2024
A survey conducted by Bloomberg Markets Live revealed that nearly 75% of the 303 respondents believe that companies selling unhealthy foods should recalibrate their business models. This could involve...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
February 19, 2024
Via
Benzinga
Novo Nordisk Has More Than Ozempic. One of Its Other Treatments Grew 393% Last Year.
February 18, 2024
It may be best known for its diabetes treatment, Ozempic, but Novo Nordisk has a host of other blockbuster drugs, too.
Via
The Motley Fool
Wealth Generators: 3 Growth Stocks You’ll Regret Not Buying in 2024
February 18, 2024
Novo Nordisk (NVO), Caterpillar (CAT), and First Solar (FSLR) are the 3 best growth stocks you'll regret now buying in 2024!
Via
InvestorPlace
22 Blue-Chip European Dividend Growth Stocks
February 16, 2024
A discussion of insights on European dividend growth stocks.
Via
Talk Markets
Meet the Next Trillion-Dollar Companies: Our Top 7 Picks
February 15, 2024
These future trillion-dollar stocks are on their way to mythic valuation, supported by strong underlying fundamentals and prospects.
Via
InvestorPlace
UK Becomes First Major Market for Eli Lilly's Mounjaro Prefilled Pen For Tackling Obesity
February 15, 2024
Eli Lilly's popular obesity and diabetes drug, Mounjaro (tirzepatide), hits the UK market this week. Superdrug and Simple Pharmacy offer accessible prescriptions for NHS and private patients.
Via
Benzinga
S&P 500's surge to new highs: Bull trap hiding in plain sight?
February 15, 2024
Nvidia and Meta lead the S&P 500 rally, but there's cause for concern about a potential bull trap amid market volatility and a pivot to stable dividend payers.
Via
MarketBeat
Topics
ETFs
Economy
Stocks
Exposures
Interest Rates
US Equities
What's Gaining Popularity Among US Teens Battling Obesity? Novo Nordisk's Weight Loss Drug Wegovy
February 15, 2024
Rise of adolescent usage of Novo Nordisk's Wegovy for pediatric obesity. Surging demand among families, but concerns linger on the impact of weight-loss drugs on growing children's development.
Via
Benzinga
7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
February 14, 2024
Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive.
Via
InvestorPlace
1 Potential Catalyst That Could Light a Fire Under Novo Nordisk's Stock This Year
February 14, 2024
Don't let the stock's high price deceive you -- Novo Nordisk can still make for a great investment.
Via
The Motley Fool
Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?
February 14, 2024
It faces both clinical and competitive barriers, but they might not matter.
Via
The Motley Fool
Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report
February 13, 2024
Kerrisdale Capital has released a short report, making clear why it is betting against ALT stock. Here's why Altimmune is likely in trouble.
Via
InvestorPlace
Altimmune Stock Sinks As Kerrisdale Capital Announces Short Position: 'Obvious Dead End'
February 13, 2024
Altimmune shares are trading lower Tuesday after short-selling investment firm Kerrisdale Capital published a new research report on the stock and announced a short position
Via
Benzinga
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
February 13, 2024
There's more for investors to get excited about in the biopharma world than just weight-loss drugs.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
February 12, 2024
Via
Benzinga
Novo Nordisk's Weight Loss Drugs Ozempic, Wegovy Show Promise For Diabetic Patients Undergoing Hip Replacement
February 12, 2024
Findings on diabetes and weight loss drugs in hip replacement. Novo Nordisk's Ozempic shows a 44% reduction in joint infections, and Wegovy proves safe, reducing complications.
Via
Benzinga
2 Value Stocks With Monster Yields
February 12, 2024
These two low-priced large-cap stocks sport ginormous yields.
Via
The Motley Fool
Novo Nordisk's Magic Run Continues Even With Increasing Competition
February 12, 2024
Novo Nordisk's Q4 earnings were rock solid as momentum in the diabetes and obesity markets continued to fuel growth.
Via
The Motley Fool
Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs
February 12, 2024
Challenges and updates in the weight loss drug market, as Novo Nordisk and Eli Lilly address supply shortages for Wegovy and Mounjaro. Strategies to meet the increasing demand and potential market...
Via
Benzinga
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
54
55
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.